Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C

Hepatology Research

Volumn 39, Issue 8, 2009, Pages 795-804

  Fabris, Carlo ^a   Smirne, Carlo ^b   Fangazio, Stefano ^b   Toniutto, Pierluigi ^a   Burlone, Michela ^b   Minisini, Rosalba ^b   Bitetto, Davide ^a   Falleti, Edmondo ^a   Cerutti, Andrea ^b   Pirisi, Mario ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Angiotensin converting enzyme; Body mass index; Hepatitis C; Lipids; Liver fibrosis; Sex

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 68349157461     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00518.x     Document Type: Article

References (54)

1. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis c and liver fibrosis. Cell Death Differ 2003; 10(Suppl 1): S59-67.
2. Feld JJ, Liang TJ. Hepatitis C - identifying patients with progressive liver injury. Hepatology 2006; 43: S194-206.
3. Gutierrez-Reyes G, Gutierrez-Ruiz MC, Kershenobich D. Liver fibrosis and chronic viral hepatitis. Arch Med Res 2007; 38: 644-51.
4. Abdalla MY, Ahmad IM, Spitz DR, Schmidt WN, Britigan BE. Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses. J Med Virol 2005; 76: 489-97.
5. Chou AH, Tsai HF, Wu YY et al. Hepatitis C virus core protein modulates TRAIL-mediated apoptosis by enhancing Bid cleavage and activation of mitochondria apoptosis signaling pathway. J Immunol 2005; 174: 2160-6.
6. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
7. Harris DR, Gonin R, Alter HJ et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120-4.
8. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36: 687-91.
9. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
10. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
11. Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33: 562-9.
12. Gaeta GB, Stornaiuolo G, Precone DF et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 2003; 39: 1036-41.
13. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology 2003; 37: 493-503.
14. Warner FJ, Lubel JS, McCaughan GW, Angus PW. Liver fibrosis: A balance of ACEs? Clin Sci (Lond) 2007; 113: 109-18.
15. Tiret L, Kee F, Poirier O etal. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet 1993; 341: 991-2.
16. Nagi DK, Foy CA, Mohamed-Ali V, Yudkin JS, Grant PJ, Knowler WC. Angiotensin-1-converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. Metabolism 1998; 47: 622-6.
17. Uemura K, Nakura J, Kohara K, Miki T. Association of ACE I/D polymorphism with cardiovascular risk factors. Hum Genet 2000; 107: 239-42.
18. Cambien F, Poirier O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
19. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/ deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20: 1433.
20. Ishak K, Baptista A, Bianchi L etal. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
21. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
22. Jonsson JR, Clouston AD, Ando Y etal. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-55.
23. Yoshiji H, Kuriyama S, Yoshii J etal. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
24. Paizis G, Gilbert RE, Cooper ME etal. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol 2001; 35: 376-85.
25. Bataller R, Gabele E, Parsons CJ et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41: 1046-55.
26. Bataller R, Gines P, Nicolas JM etal. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
27. Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003; 139: 1085-94.
28. Yokohama S, Yoneda M, Haneda M et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-5.
29. Yokohama S, Tokusashi Y, Nakamura K etal. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12: 322-6.
30. Debernardi-Venon W, Martini S, Biasi F et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol 2007; 46: 1026-33.
31. Terui Y, Saito T, Watanabe H etal. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology 2002; 36: 1022.
32. Yoshiji H, Noguchi R, Fukui H. Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol 2005; 40: 215-6.
33. Rimola A, Londono MC, Guevara G et al. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation 2004; 78: 686-91.
34. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828-33.
35. Forrest EH, Thorburn D, Spence E et al. Polymorphisms of the renin-angiotensin system and the severity of fibrosis in chronic hepatitis C virus infection. J Viral Hepat 2005; 12: 519-24.
36. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002; 53: 672-7.
37. Ruixing Y, Jinzhen W, Shangling P, Weixiong L, Dezhai Y, Yuming C. Sex differences in environmental and genetic factors for hypertension. Am J Med 2008; 121: 811-9.
38. Petrovic D, Bregar D, Guzic-Salobir B et al. Sex difference in the effect of ACE-DD genotype on the risk of premature myocardial infarction. Angiology 2004; 55: 155-8.
39. Sullivan JC. Sex and the renin-angiotensin system: Inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol 2008; 294: R1220-6.
40. Strazzullo P, Iacone R, Iacoviello L et al. Genetic variation in the renin-angiotensin system and abdominal adiposity in men: The Olivetti Prospective Heart Study. Ann Intern Med 2003; 138: 17-23.
41. Toniutto P, Fabris C, Minisini R et al. Weight gain after liver transplantation and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Transplantation 2005; 79: 1338-43.
42. Oren I, Brook JG, Gershoni-Baruch R et al. The D allele of the angiotensin-converting enzyme gene contributes towards blood LDL-cholesterol levels and the presence of hypertension. Atherosclerosis 1999; 145: 267-71.
43. del Ser T, Bornstein B, Barba R, Cemillan C. Relationship of angiotensin converting enzyme genotype with serum triglyceride concentration in stroke patients. Neurosci Lett 2001; 316: 21-4.
44. You CH, Hong YS, Kwak JY et al. [The relationship between ACE I/D polymorphism and HDL cholesterol]. J Prev Med Public Health 2006; 39: 505-10.
45. Wilsgaard T, Arnesen E. Change in serum lipids and body mass index by age, sex, and smoking status: The Tromso study 1986-1995. Ann Epidemiol 2004; 14: 265-73.
46. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: Differences related to viral etiology. Clin Chim Acta 1997; 261: 159-65.
47. Siagris D, Christofidou M, Theocharis GJ et al. Serum lipid pattern in chronic hepatitis C: Histological and virological correlations. J Viral Hepat 2006; 13: 56-61.
48. Marzouk D, Sass J, Bakr I et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56: 1105-10.
49. Dai CY, Chuang WL, Ho CK et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: A community-based study. J Hepatol 2008; 49: 9-16.
50. Andre P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-28.
51. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
52. Monazahian M, Bohme I, Bonk S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57: 223-9.
53. Hennig BJ, Hellier S, Frodsham AJ et al. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002; 3: 359-67.
54. Li H, Liu Z, Han Q, Li Y, Chen J. Association of genetic polymorphism of low-density lipoprotein receptor with chronic viral hepatitis C infection in Han Chinese. J Med Virol 2006; 78: 1289-95.